BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
10 Enero 2024 - 6:30AM
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the
“Company”), a commercial-stage biopharmaceutical company focused on
genetic diseases and cancers, today announced that on January 08,
2024, the compensation committee of BridgeBio’s board of directors
granted twenty five new employees restricted stock units for an
aggregate of 66,963 shares of the Company’s common stock.
One-fourth of the shares underlying each employee’s restricted
stock units will vest on February 16, 2025, with one-twelfth of the
remaining shares underlying each such employee’s restricted stock
units vesting on a quarterly basis thereafter, in each case,
subject to each such employee’s continued employment with the
Company or one of its subsidiaries on such vesting dates. All of
the above-described awards were made under BridgeBio’s Amended and
Restated 2019 Inducement Equity Plan (the “Plan”).
The above-described awards were each granted as an inducement
material to the employees entering into employment with the Company
in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted
pursuant to the terms of the Plan. The Plan was adopted by
BridgeBio’s board of directors in November 2019, and amended and
restated on February 10, 2023 and on December 13, 2023.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical
company founded to discover, create, test, and deliver
transformative medicines to treat patients who suffer from genetic
diseases and cancers with clear genetic drivers. BridgeBio’s
pipeline of development programs ranges from early science to
advanced clinical trials. BridgeBio was founded in 2015 and its
team of experienced drug discoverers, developers and innovators are
committed to applying advances in genetic medicine to help patients
as quickly as possible. For more information visit bridgebio.com
and follow us on LinkedIn and Twitter.
BridgeBio Contact:
Vikram Balicontact@bridgebio.com(650)-789-8220
BridgeBio Pharma (NASDAQ:BBIO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
BridgeBio Pharma (NASDAQ:BBIO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024